Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025
Rhea-AI Summary
Reviva (NASDAQ: RVPH) will present data on negative symptoms for brilaroxazine from the Phase 3 RECOVER program at CNS Summit 2025 in Boston.
The presentation covers results from the double‑blind RECOVER trial in acute exacerbation of schizophrenia and the long‑term open‑label extension in clinically stable patients over one year. Poster Number 32 is scheduled for Nov 3 and Nov 4, 2025, 5:00–7:00 PM ET. The conference runs Nov 2–5, 2025. Abstracts and additional details are available on the CNS Summit 2025 website.
Positive
- None.
Negative
- None.
News Market Reaction 4 Alerts
On the day this news was published, RVPH declined 2.42%, reflecting a moderate negative market reaction. Argus tracked a peak move of +9.6% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $60M at that time.
Data tracked by StockTitan Argus on the day of publication.
CUPERTINO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that negative symptom data for brilaroxazine from the Phase 3 RECOVER double-blind trial in patients with acute exacerbation of schizophrenia, and from the long-term open-label extension trial in clinically stable schizophrenia patients will be presented as a poster presentation at the CNS Summit 2025, taking place November 2-5, in Boston, Massachusetts.
Details for the poster presentation can be found below:
Title: Brilaroxazine Treatment Effect on Negative Symptoms in Schizophrenia: RECOVER Trial in Acute and Stable Patients Over 1 Year
Poster Number: 32
Date and Time: Monday, November 3rd and Tuesday November 4th from 5:00- 7:00 PM ET
Abstracts and additional details can be found at the CNS Summit 2025 website.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com
FAQ
What data will Reviva (RVPH) present at CNS Summit 2025?
When and where is Reviva's brilaroxazine poster presentation (RVPH)?
What patient populations are included in the RECOVER brilaroxazine data for RVPH?
How long is the follow‑up reported for the open‑label extension in the RVPH poster?
Where can investors find the abstract and full poster details for RVPH at CNS Summit 2025?
